Overview
This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.
Description
The trophoblast cell surface antigen 2 (Trop2), encoded by the TACSTD2 gene, is a transmembrane glycoprotein that regulates epithelial malignant transformation and proliferation. Trop2 has been reported to be overexpressed in various epithelial tumors, including craniopharyngioma. 68Ga-MY6349, an immune-PET tracer targeting Trop2, has demonstrated high specificity and sensitivity in visualizing other Trop2-high solid tumors. In this research, patients with primary or recurrent craniopharyngioma scheduled for surgery will receive the preoperative 68Ga-MY6349 PET/CT in addition to standard MRI. Tumor uptake is quantified by the maximum standardized uptake value (SUVmax). The diagnostic performance of 68Ga-MY6349 PET is subsequently compared with MRI and the SUVmax is correlated with Trop2 expression levels in postoperative pathological specimens.
Eligibility
Inclusion criteria:
- must be able to provide a written informed consent
- radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
- adequate clinical condition (Karnofsky performance status ≥70)
Exclusion criteria:
- concomitant major central nervous system disorders
- severe hepatic or renal dysfunction
- history of severe allergy or hypersensitivity to intravenous radiographic contrast agents
- claustrophobia precluding PET/CT or MRI examinations
- pregnancy or breastfeeding